- Home
- ARMP vs ATRA Comparison
ARMP vs ATRA Comparison
Compare ARMP & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- ATRA
- Stock Information
- Founded
- ARMP N/A
- ATRA 2012
- Country
- ARMP United States
- ATRA United States
- Employees
- ARMP N/A
- ATRA N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARMP Health Care
- ATRA Health Care
- Exchange
- ARMP Nasdaq
- ATRA Nasdaq
- Market Cap
- ARMP 52.1M
- ATRA 51.1M
- IPO Year
- ARMP N/A
- ATRA 2014
- Fundamental
- Price
- ARMP $2.22
- ATRA $9.23
- Analyst Decision
- ARMP Strong Buy
- ATRA Buy
- Analyst Count
- ARMP 1
- ATRA 5
- Target Price
- ARMP $9.00
- ATRA $17.75
- AVG Volume (30 Days)
- ARMP 18.4K
- ATRA 34.5K
- Earning Date
- ARMP 08-12-2025
- ATRA 08-11-2025
- Dividend Yield
- ARMP N/A
- ATRA N/A
- EPS Growth
- ARMP N/A
- ATRA N/A
- EPS
- ARMP N/A
- ATRA N/A
- Revenue
- ARMP $4,699,000.00
- ATRA $199,732,000.00
- Revenue This Year
- ARMP $8.43
- ATRA N/A
- Revenue Next Year
- ARMP N/A
- ATRA N/A
- P/E Ratio
- ARMP N/A
- ATRA N/A
- Revenue Growth
- ARMP 14.24
- ATRA 475.53
- 52 Week Low
- ARMP $0.90
- ATRA $5.01
- 52 Week High
- ARMP $3.42
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- ARMP 63.56
- ATRA 64.09
- Support Level
- ARMP $1.93
- ATRA $7.54
- Resistance Level
- ARMP $2.24
- ATRA $8.25
- Average True Range (ATR)
- ARMP 0.16
- ATRA 0.47
- MACD
- ARMP 0.03
- ATRA 0.12
- Stochastic Oscillator
- ARMP 104.55
- ATRA 81.93
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).